Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 5461 Titration Study in MDD
NCT02085135Phase 3Completed
- Sponsor
- Alkermes
- Start
- Feb 2014
- Primary completion
- Sep 2014
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of buprenorphine + samidorphan in major depressive disorder (MDD) (2 arms), sponsored by Alkermes. Primary endpoint: Number of Subjects With Adverse Events at 8 weeks. Started Feb 2014; status: completed.
02
Drugs
buprenorphine + samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02085135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085135.